Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Phase 3 Trial Using the SYK inhibitor, Entospletinib, in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed, NPM1 Mutated Acute Myelogenous Leukemia
NCT Number:
NCT05020665
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Myeloid and Monocytic Leukemia
Study Objectives:
The primary objective of this study is to evaluate the efficacy of entospletinib (ENTO) compared to placebo when added to chemotherapy in previously untreated nucleophosmin-1 mutated (NPM1-m) acute myeloid leukemia (AML), as defined by the rate of molecularly defined measurable residual disease (MRD).
Study Documents
(MUSC NetID required for document access)